To illustrate the principles of next-generation antibody engineering in multiple myeloma, we refer to a previously reported example of a T-cell–redirecting antibody targeting CD38 and CD3, designated tri-31C2 (Figure 2) [18]. This evidence concerns the gene CD38 and AL amyloidosis.